Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National Cancer Centre
Tan Tock Seng Hospital
Trial Status: Ongoing, Recruiting
Principal Investigator(s):
Dr Johan Chan
Dr Elise Vong
Published by HT Digital Content Services with permission from Health Daily Digest....